Barclays PLC Sells 777,507 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Barclays PLC cut its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 89.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,767 shares of the company's stock after selling 777,507 shares during the quarter. Barclays PLC owned 0.08% of Karyopharm Therapeutics worth $79,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock valued at $649,000 after acquiring an additional 622,194 shares during the period. Cubist Systematic Strategies LLC bought a new position in Karyopharm Therapeutics during the 2nd quarter worth $494,000. GSA Capital Partners LLP lifted its holdings in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock worth $1,474,000 after buying an additional 792,283 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $167,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $31,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Stock Performance

Shares of KPTI stock traded up $0.00 during trading hours on Friday, hitting $0.72. 847,414 shares of the company were exchanged, compared to its average volume of 1,042,369. Karyopharm Therapeutics Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $1.95. The company has a 50 day simple moving average of $0.77 and a two-hundred day simple moving average of $0.82. The firm has a market cap of $90.68 million, a P/E ratio of -0.63 and a beta of 0.07.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same quarter in the prior year, the company posted ($0.30) EPS. As a group, sell-side analysts expect that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. StockNews.com lowered Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Finally, Piper Sandler increased their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).